Article
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing.
Clinical pharmacology and therapeutics - 1 Jun 2021
Lima John J, Thomas Cameron D, Barbarino Julia, Desta Zeruesenay, Van Driest Sara L, El Rouby Nihal, Johnson Julie A, Cavallari Larisa H, Shakhnovich Valentina, Thacker David L, Scott Stuart A, Schwab Matthias, Uppugunduri Chakradhara Rao S, Formea Christine M, Franciosi James P, Sangkuhl Katrin, Gaedigk Andrea, Klein Teri E, Gammal Roseann S, Furuta Takahisa
Abstract excerpt
Proton pump inhibitors (PPIs) are widely used for acid suppression in the treatment and prevention of many conditions, including gastroesophageal reflux disease, gastric and duodenal ulcers, erosive esophagitis, Helicobacter pylori infection, and pathological hypersecretory conditions. Most PPIs are metabolized primarily by cytochrome P450 2C19 (CYP2C19) into inactive metabolites, and CYP2C19 genotype has been...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.